MetaCap

Beta Bionics Inc. (BBNX)

NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD

13.36+0.04 (+0.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BBNX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$726.34M
EPS (TTM)
-$1.83
52-week range
8.80 – 32.71
Day range
12.92 – 13.85
Volume / Avg
960.30K / 1.21M
Beta
—

52-week range

$8.80$32.71

BBNX stock today

Shares of Beta Bionics (BBNX) finished higher on Nov 20 at $13.36, a gain of 0.30% or $0.04 per share, versus the S&P 500's 3.70% decline. At this level, BBNX sits near the bottom of its 52-week range of $8.80 to $32.71: 59.2% below the high, set on Nov 26, 2025 and 51.8% above the low. BBNX is down 56.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.5%.

Beta Bionics has posted a net loss over the last twelve months (EPS of -$1.83), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Beta Bionics

Company profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.

Industry
Medical/Dental Instruments
CEO
Mr. Sean T. Saint PE
Headquarters
Irvine, CA
Employees
420
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Beta Bionics generated $100.3 million in revenue, up 53.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Beta Bionics reported a net loss of $73.2 million, compared with a loss of $54.8 million a year earlier. Gross margin was 55.4% (up from 55.1%) and operating margin -71.5%.

Beta Bionics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$100.25M$65.12M$11.99M
Growth+53.94%+442.93%—
Net income$-73.20M$-54.76M$-44.10M
EPS (diluted)$-1.81$-8.60$-8.31

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$25.10+87.87%

  • Strong buy 2
  • Buy 9
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $30.40

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$-0.52 vs $-0.53
Surprise
+1.89%

BBNX news

All BBNX news

Beta Bionics peers

Health Care sector
BBNX peer companies
CompanyPrice% ChgMarket capCompare
VVVVvVARDIS Holding AG Class A14.55-3.00%$770.91Mvs BBNX
BVSBioventus Inc. Class A9.88-0.70%$676.53Mvs BBNX
DCTHDelcath Systems Inc.18.79-2.34%$653.67Mvs BBNX
KIDSOrthoPediatrics Corp.31.74-2.37%$828.75Mvs BBNX
TCMDTactile Systems Technology Inc.25.60-1.50%$573.48Mvs BBNX
SGHTSight Sciences Inc.10.18-4.14%$565.79Mvs BBNX
AORTArtivion Inc.18.16-2.00%$886.02Mvs BBNX
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs BBNX

Indexes, lists and sector

Beta Bionics stock FAQ

What is Beta Bionics's stock price today?

BBNX last traded at $13.36 as of Nov 20, 4:00 PM EST, up 0.30% on the day. Prices are delayed at least 15 minutes.

Who is Beta Bionics's CEO?

Mr. Sean T. Saint PE is the chief executive officer of Beta Bionics Inc., which has about 420 employees.

What is the BBNX 52-week high?

The 52-week high for BBNX is $32.71 and the 52-week low is $8.80. The stock is currently 59.2% below its high.

Compare BBNX